Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bupivacaine + morphine is a combination analgesic regimen administered via paravertebral block (PVB) for the management of acute postoperative pain. This specific formulation, investigated by Assiut University, utilizes morphine as an adjuvant to the local anesthetic bupivacaine. Morphine acts as a potent mu-opioid receptor agonist, providing analgesia through the modulation of pain perception in the central nervous system. Bupivacaine is a long-acting local anesthetic that functions by blocking voltage-gated sodium channels, thereby inhibiting nerve impulse conduction in the paravertebral space. The combination is primarily studied for its efficacy in reducing pain scores and opioid consumption following major surgical procedures, such as breast and renal surgeries.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bupivacaine + morphine (Assiut University).